As Celltrion releases new data on its subcutaneous infliximab product in gastroenterology conditions, Samsung Bioepis secures an interchangeability designation for Byooviz, making it the second ranibizumab biosimilar to be deemed interchangeable with the reference product.
As Celltrion releases new data on its subcutaneous infliximab product, Samsung Bioepis secures an interchangeability designation for Byooviz (ranibizumab-nuna), making it the second ranibizumab biosimilar to be deemed interchangeable with the reference product.
Byooviz Interchangeability
Byooviz has become the second ranibizumab/ophthalmology biosimilar to receive an interchangeability designation. The news comes a little over a year after Cimerli, Coherus Biosciences’ ranibizumab product, was granted interchangeability in August 2022.
The FDA approved Byooviz as the first ranibizumab/ophthalmology biosimilar to Lucentis (reference ranibizumab) in September. Ranibizumab products are vascular endothelial growth factor inhibitors used to treat several ophthalmic conditions, including age-related macular degeneration, macular edema, diabetic retinopathy, and myopic choroidal neovascularization.
To obtain the designation, the FDA requires information that shows that “the risk in terms of safety or diminished efficacy of alternating or switching between use of the product and its reference product is not greater than the risk of using the reference product without such alternation or switch.”
In most cases, this is demonstrated with data from a switching study, where patients are switched back and forth several times between the reference product and biosimilar to prove that transitioning is safe and doesn’t impact clinical outcomes. However, Sarah Yim, MD, director of the FDA’s Office of Therapeutic and Biologics and Biosimilars, said that the intravitreal administration of ranibizumab products doesn’t warrant the need for a switching study because there is a low risk of immunogenic response within the eye.
Byooviz was developed by Samsung Bioepis and is marketed in the United States by Biogen. The companies have been in an exclusive commercialization agreement for Byooviz and SB15, an aflibercept candidate, since November 2019.
Celltrion Data on Subcutaneous Infliximab
At the United European Gastroenterology Week 2023, Celltrion shared updated data from its phase 3 LIBERTY trials assessing the use of the company’s subcutaneous infliximab product (CT-P13 SC) in patients with inflammatory bowel disease (IBD), an umbrella term for ulcerative colitis (UC) and Crohn disease (CD).
The study results demonstrated that CT-P13 SC has a similar safety profile to the placebo during the maintenance period (54 weeks). The proportion of patients who experienced adverse events, serious adverse events, inflection in both treatment arms were comparable. No new safety concerns were identified.
Additionally, results from 2 post-hoc analyses were presented. The first examined the possible use of CT-P13 SC treatment without immunosuppressants, showing that use of the product as a monotherapy was safe for patients with UC and CD, suggesting that combination therapy with CT-P13 and immunosuppressants would have little benefit for these patients.
The second analysis assessed dose escalation in patients with loss of treatment response. The recommended dose for CT-P13 SC is 120 mg once every 2 weeks. Exploratory results suggest that dose escalation from 120mg to 240mg every 2 weeks may restore efficacy, while safety profiles were shown to be comparable between patients with or without dose escalation. In both studies, patients showed improvement in terms of clinical remission (UC: 24.7%, n = 20/81; CD: 53.8%, n = 21/39) or endoscopic response (CD: 28.2%, n = 11/39) after dose escalation.
Celltrion also presented real-world data on switching from its intravenous infliximab biosimilar to CT-P13 SC in a separate presentation at the conference. “The findings may help support the practical application of this innovation,” Celltrion wrote.
The product was based on Celltrion’s infliximab biosimilar (Inflectra; infliximab-dyyb) and is the only subcutaneous infliximab in the world. Earlier this week, the FDA approved the product and it will be marketed as Zymfentra, which is also available in the European Union as Remsima SC.
“As a healthcare professional dedicated to improving the lives of IBD patients, I am excited to see further data that validate a subcutaneous treatment option allowing more patients in the U.S. to have greater control of their disease,” Stephen B. Hanauer, MD, medical director of the Digestive Health Center at Northwestern Medicine, and professor of medicine at the Feinberg School of Medicine, said in a statement from Celltrion.
Decoding the Patent Puzzle: Navigating the Legal Landscape of Biosimilars
March 17th 2024On this episode of Not So Different, Ha Kung Wong, JD, an intellectual patent attorney and partner at Venable LLP, details the confusing landscape that is the US patent system and how it can be improved to help companies overcome barriers to biosimilar competition.
Eye on Pharma: EU Ustekinumab Approval; New Golimumab Data; Evernorth Adds Humira Biosimilar
April 29th 2024The European Union gained a new ustekinumab biosimilar; Alvotech released positive results from a clinical trial evaluating a golimumab biosimilar and the reference products (Simponi and Simponi Aria), and Evernorth announced that it is set to cover an adalimumab biosimilar at zero cost to patients.
Biosimilars Rheumatology Roundup for February 2024—Podcast Edition
March 3rd 2024On this episode of Not So Different, The Center for Biosimilars® revisited all the major rheumatology biosimilar news from February 2024, including the FDA approval of the 10th adalimumab biosimilar, the promise for an oral delivery system for ustekinumab, and the impact of adalimumab products on COVID-19 antibodies.
Patient Perceptions of Switching From the Reference Adalimumab to Amjevita During Its Initial Launch
April 20th 2024In a survey of patients with autoimmune arthritis who had been switched from reference adalimumab (Humira) to biosimilar adalimumab-atto (Amjevita; Amgen), most reported preferring the biosimilar and had no concerns about switching.
Julie Reed: Why 2024 Is Important for Biosimilars
April 17th 2024Julie Reed, executive director of the Biosimilars Forum, showcases how the biosimilar industry is expected to develop throughout 2024, including major policy changes and hope for continued improvement in market share for adalimumab biosimilars.